Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine DOI Creative Commons

Edmund G. Wee,

Sarah Kempster, David Ferguson

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(9), P. 965 - 965

Published: Aug. 26, 2024

During the COVID-19 pandemic, antibody-based vaccines targeting SARS-CoV-2 spike glycoprotein were focus for development because neutralizing antibodies associated with protection against infection pre-clinically and in humans. While deploying these spike-based saved millions of lives worldwide, it has become clear that immunological mechanisms severe disease are multifaceted involve non-neutralizing antibody components. Here, we describe a novel pan-sarbecovirus T-cell vaccine, ChAdOx1.COVconsv12, designed to complement broaden vaccines. The vaccine immunogen COVconsv12 employs two regions viral proteome most conserved among sarbecoviruses, which delivered by replication-deficient vector ChAdOx1. It directs T cells towards epitopes shared sarbecoviruses including evolving variants. show ChAdOx1.COVconsv12 induced broad responses BALB/c C57BL/6 mice. In Syrian hamster challenge model, alone did not protect infection, but when co-administered 1/50th ChAdOx1 nCoV-19 protective dose, faster recovery lower oral swab load observed. Induction CD8+ may decrease severity extend response coverage variants match known (and as yet unknown) members β-coronavirus family.

Language: Английский

Re-emergence of severe acute diarrhea syndrome coronavirus (SADS-CoV) in Henan, central China, 2023 DOI
Teng Zhang,

Jiale Yao,

Zhuan Yang

et al.

Veterinary Microbiology, Journal Year: 2024, Volume and Issue: 292, P. 110049 - 110049

Published: March 15, 2024

Language: Английский

Citations

8
A comprehensive dataset of animal-associated sarbecoviruses DOI Creative Commons
Bo Liu, Peng Zhao, Panpan Xu

et al.

Scientific Data, Journal Year: 2023, Volume and Issue: 10(1)

Published: Oct. 7, 2023

Language: Английский

Citations

3
Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine DOI Creative Commons

Edmund G. Wee,

Sarah Kempster, David Ferguson

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(9), P. 965 - 965

Published: Aug. 26, 2024

During the COVID-19 pandemic, antibody-based vaccines targeting SARS-CoV-2 spike glycoprotein were focus for development because neutralizing antibodies associated with protection against infection pre-clinically and in humans. While deploying these spike-based saved millions of lives worldwide, it has become clear that immunological mechanisms severe disease are multifaceted involve non-neutralizing antibody components. Here, we describe a novel pan-sarbecovirus T-cell vaccine, ChAdOx1.COVconsv12, designed to complement broaden vaccines. The vaccine immunogen COVconsv12 employs two regions viral proteome most conserved among sarbecoviruses, which delivered by replication-deficient vector ChAdOx1. It directs T cells towards epitopes shared sarbecoviruses including evolving variants. show ChAdOx1.COVconsv12 induced broad responses BALB/c C57BL/6 mice. In Syrian hamster challenge model, alone did not protect infection, but when co-administered 1/50th ChAdOx1 nCoV-19 protective dose, faster recovery lower oral swab load observed. Induction CD8+ may decrease severity extend response coverage variants match known (and as yet unknown) members β-coronavirus family.

Language: Английский

Citations

0